113 related articles for article (PubMed ID: 24366939)
1. Targeted cancer therapy: from bench to bedside to patient.
Gellad WF
J Clin Oncol; 2014 Feb; 32(4):268-70. PubMed ID: 24366939
[No Abstract] [Full Text] [Related]
2. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
4. With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Tuma RS
J Natl Cancer Inst; 2007 Feb; 99(3):192-4. PubMed ID: 17284712
[No Abstract] [Full Text] [Related]
5. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
[TBL] [Abstract][Full Text] [Related]
6. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
Soysal T; Eskazan AE; Ar MC
Expert Rev Hematol; 2014 Dec; 7(6):697-9. PubMed ID: 25292262
[TBL] [Abstract][Full Text] [Related]
7. Position paper on imatinib mesylate in chronic myeloid leukaemia.
O'Brien SG; Rule SA
Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
[No Abstract] [Full Text] [Related]
8. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
Conti RM; Padula WV; Larson RA
Ann Hematol; 2015 Apr; 94 Suppl 2(0 2):S249-57. PubMed ID: 25814091
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Taylor MJ; Scuffham PA
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Garside R; Round A; Dalziel K; Stein K; Royle P
Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
[No Abstract] [Full Text] [Related]
11. Chronic myelogenous leukemia.
Klemm J; Mehr SR
Am J Manag Care; 2012 May; 18(3 Spec No.):SP105-7. PubMed ID: 22642273
[No Abstract] [Full Text] [Related]
12. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
13. NICE backs leukaemia drug after manufacturer drops price.
Wise J
BMJ; 2012 Mar; 344():e2274. PubMed ID: 22442356
[No Abstract] [Full Text] [Related]
14. Imatinib for chronic myeloid leukaemia: a NICE mess.
O'Brien SG
Lancet; 2001 Dec; 358(9296):1902-3. PubMed ID: 11741654
[No Abstract] [Full Text] [Related]
15. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Jabbour EJ; Kantarjian H; Eliasson L; Cornelison AM; Marin D
Am J Hematol; 2012 Jul; 87(7):687-91. PubMed ID: 22473898
[TBL] [Abstract][Full Text] [Related]
16. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
17. Imatinib for chronic myeloid leukaemia: a NICE mess.
Barbour V
Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
[No Abstract] [Full Text] [Related]
18. Imatinib for chronic myeloid leukaemia: a NICE mess.
Rajaratnam G; Edwards J
Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
[No Abstract] [Full Text] [Related]
19. [Induction of hospital indebtedness due to medicine purchases under monopoly conditions: the case of imatinib mesylate].
Scopel CT; Chaves GC
Cad Saude Publica; 2015 Mar; 31(3):575-85. PubMed ID: 25859724
[TBL] [Abstract][Full Text] [Related]
20. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
Kimura S; Kako S; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Watanabe T; Kanda Y
Leuk Res; 2011 Jan; 35(1):e11-2. PubMed ID: 20952061
[No Abstract] [Full Text] [Related]
[Next] [New Search]